Drug Search Results
More Filters [+]

Torcetrapib

Alternative Names: torcetrapib
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CETP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Torcetrapib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hyperlipidemia|Hypercholesterolemia|Hyperlipoproteinemia Type II|Hyperlipoproteinemias|Hyperlipoproteinemia Type III|Dyslipidemia|Coronary Artery Disease|Coronary Disease|Hyperlipoproteinemia Type IV|Hypertriglyceridemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ILLUMINATE

P3

Terminated

Coronary Artery Disease

2007-06-01

2004-000156-16

P3

Terminated

Coronary Disease

2006-12-02

A5091031

P3

Terminated

Dyslipidemia|Hyperlipidemia|Hyperlipoproteinemias|Hypercholesterolemia

2006-12-01

A5091024

P3

Terminated

Hyperlipoproteinemia Type III|Hyperlipoproteinemias|Hyperlipidemia

2006-12-01

Recent News Events